Universal Stabilization Technologies (Vitrilife)

Universal Stabilization Technologies (UST) has developed the VitriLife® platform, a patented technology that transforms temperature-sensitive vaccines and biologics into shelf-stable formats. This addresses the critical global challenge of cold chain dependency, which is costly, inefficient, and a barrier to access in low-resource settings. The platform offers superior alternatives to traditional lyophilization and needle-based delivery, with applications across vaccines, immunotherapies, and fragile biologics. UST operates as a technology provider and development partner for pharmaceutical companies, aiming to enable global distribution of life-saving medicines.

VitriLife® - A patented thermostabilization platform that transforms temperature-sensitive vaccines and biologics into shelf-stable formats for ambient storage and transport, coupled with development of novel mucosal and transdermal delivery systems.

UST competes with traditional lyophilization service providers, specialty contract development and manufacturing organizations (CDMOs) with formulation expertise, and other biotech startups developing alternative stabilization technologies. Large pharma companies also have internal formulation groups working on similar challenges.